| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Medical Microbiology, Malmö University Hospital, Entrance 78, S-20502 Malmö, Sweden
2 Institute of Biotechnology, Graiciuno 8, LT-2028, Vilnius, Lithuania
3 Department of Microbiology, National Public Health Institute, PO Box 310 (Aapistie 1), FIN-90101 Oulu, Finland
4 Department of Infectious Disease Epidemiology, National Public Health Institute, Mannerheimintie 166, FIN-00300 Helsinki, Finland
Correspondence
Joakim Dillner
joakim.dillner{at}mikrobiol.mas.lu.se
To assess the stability of polyomavirus antibodies in serial samples over time and the incidence and age-specific prevalence of polyomavirus infections, we established enzyme immunoassays (EIAs) using purified yeast-expressed virus-like particles (VLPs) containing the VP1 major capsid proteins of JC virus (JCV) and the AS and SB strains of BK virus (BKV). A random subsample of 150 Finnish women who had serum samples taken during the first trimester of pregnancy and had a second pregnancy during a 5 year follow-up period was selected, grouped by age of first pregnancy. The polyomavirus antibody levels were similar in samples taken during the first and second pregnancies (correlation coefficient 0·93 for BKV SB and 0·94 for JCV). Analysis of serum samples from 290 Swedish children aged 1–13 years, grouped by age in 2 year intervals, demonstrated that BKV seropositivity increased rapidly with increasing age of the children, reaching 98 % seroprevalence at 7–9 years of age, followed by a minor decrease. JCV seroprevalence increased only slowly with increasing age and reaching 72 % positivity among mothers >25 years of age. The age-specific seroprevalence of the human polyomaviruses measured using this VLP-based EIA was similar to previous serosurveys by other methods. The stability of the antibodies over time indicates that polyomavirus seropositivity is a valid marker of cumulative virus exposure, and polyoma VLP-based EIAs may therefore be useful for epidemiological studies of these viruses.
This article has been cited by other articles:
|
|
 |
|
  S. Bodaghi, P. Comoli, R. Bosch, A. Azzi, R. Gosert, D. Leuenberger, F. Ginevri, and H. H. Hirsch Antibody Responses to Recombinant Polyomavirus BK Large T and VP1 Proteins in Young Kidney Transplant Patients J. Clin. Microbiol., August 1, 2009; 47(8): 2577 - 2585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Vanchiere, S. Abudayyeh, C. M. Copeland, L. B. Lu, D. Y. Graham, and J. S. Butel Polyomavirus Shedding in the Stool of Healthy Adults J. Clin. Microbiol., August 1, 2009; 47(8): 2388 - 2391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Iacobaeus, C Ryschkewitsch, M Gravell, M Khademi, E Wallstrom, T Olsson, L Brundin, and E. Major Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA Multiple Sclerosis, January 1, 2009; 15(1): 28 - 35. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Gosert, C. H. Rinaldo, G. A. Funk, A. Egli, E. Ramos, C. B. Drachenberg, and H. H. Hirsch Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology J. Exp. Med., April 14, 2008; 205(4): 841 - 852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Beimler, C. Sommerer, and M. Zeier The influence of immunosuppression on the development of BK virus nephropathy does it matter? Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_8): viii66 - viii71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. P Thamboo, K. J M Jeffery, P. J Friend, G. D H Turner, and I. S D Roberts Urine cytology screening for polyoma virus infection following renal transplantation: the Oxford experience J. Clin. Pathol., August 1, 2007; 60(8): 927 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Bohl and D. C. Brennan BK Virus Nephropathy and Kidney Transplantation Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(Supplement_1): S36 - S46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Randhawa, G. Gupta, A. Vats, R. Shapiro, and R. P. Viscidi Immunoglobulin G, A, and M Responses to BK Virus in Renal Transplantation. Clin. Vaccine Immunol., September 1, 2006; 13(9): 1057 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Perez-Losada, R. G. Christensen, D. A. McClellan, B. J. Adams, R. P. Viscidi, J. C. Demma, and K. A. Crandall Comparing Phylogenetic Codivergence between Polyomaviruses and Their Hosts. J. Virol., June 1, 2006; 80(12): 5663 - 5669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Moret, V. Brodard, C. Barranger, N. Jovenin, M. Joannes, and L. Andreoletti New Commercially Available PCR and Microplate Hybridization Assay for Detection and Differentiation of Human Polyomaviruses JC and BK in Cerebrospinal Fluid, Serum, and Urine Samples J. Clin. Microbiol., April 1, 2006; 44(4): 1305 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.K. Kleinschmidt-DeMasters and K. L. Tyler Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis N. Engl. J. Med., July 28, 2005; 353(4): 369 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lundstig, L. Eliasson, M. Lehtinen, K. Sasnauskas, P. Koskela, and J. Dillner Prevalence and stability of human serum antibodies to simian virus 40 VP1 virus-like particles J. Gen. Virol., June 1, 2005; 86(6): 1703 - 1708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Engels, J. Chen, R. P. Viscidi, K. V. Shah, R. W. Daniel, N. Chatterjee, and M. A. Klebanoff Poliovirus Vaccination during Pregnancy, Maternal Seroconversion to Simian Virus 40, and Risk of Childhood Cancer Am. J. Epidemiol., August 15, 2004; 160(4): 306 - 316. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |
